Virtus ETF Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-46,007
| Closed | -$346K | – | 464 |
|
|
2024
Q4 | $346K | Sell |
46,007
-6,858
| -13% | -$52.1K | 0.14% | 204 |
|
|
2024
Q3 | $402K | Hold |
52,865
| – | – | 0.19% | 203 |
|
|
2024
Q2 | $327K | Sell |
52,865
-6,392
| -11% | -$35.3K | 0.16% | 214 |
|
|
2024
Q1 | $301K | Buy |
59,257
+8,526
| +17% | +$47.9K | 0.16% | 227 |
|
|
2023
Q4 | $304K | Buy |
50,731
+12,410
| +32% | +$71.9K | 0.19% | 223 |
|
|
2023
Q3 | $271K | Sell |
38,321
-4,957
| -11% | -$35.6K | 0.16% | 215 |
|
|
2023
Q2 | $305K | Buy |
43,278
+15,707
| +57% | +$126K | 0.18% | 204 |
|
|
2023
Q1 | $230K | Buy |
27,571
+485
| +2% | +$4.67K | 0.13% | 295 |
|
|
2022
Q4 | $311K | Buy |
27,086
+2,166
| +9% | +$27K | 0.16% | 247 |
|
|
2022
Q3 | $314K | Buy |
24,920
+364
| +1% | +$4.68K | 0.13% | 270 |
|
|
2022
Q2 | $260K | Sell |
24,556
-7,986
| -25% | -$82.4K | 0.1% | 288 |
|
|
2022
Q1 | $529K | Hold |
32,542
| – | – | 0.24% | 116 |
|
|
2021
Q4 | $451K | Buy |
32,542
+4,452
| +16% | +$58.9K | 0.17% | 124 |
|
|
2021
Q3 | $404K | Sell |
28,090
-2,579
| -8% | -$40.7K | 0.18% | 173 |
|
|
2021
Q2 | $485K | Sell |
30,669
-4,662
| -13% | -$63.3K | 0.2% | 157 |
|
|
2021
Q1 | $359K | Buy |
35,331
+624
| +2% | +$6.43K | 0.15% | 203 |
|
|
2020
Q4 | $259K | Sell |
34,707
-37,137
| -52% | -$191K | 0.11% | 299 |
|
|
2020
Q3 | $247K | Sell |
71,844
-9,800
| -12% | -$42K | 0.13% | 265 |
|
|
2020
Q2 | $389K | Sell |
81,644
-39,414
| -33% | -$157K | 0.18% | 210 |
|
|
2020
Q1 | $242K | Sell |
121,058
-17,661
| -13% | -$48.6K | 0.1% | 257 |
|
|
2019
Q4 | $479K | Buy |
138,719
+64,186
| +86% | +$161K | 0.08% | 207 |
|
|
2019
Q3 | $214K | Sell |
74,533
-4,151
| -5% | -$12.9K | 0.04% | 234 |
|
|
2019
Q2 | $298K | Buy |
78,684
+47,407
| +152% | +$285K | 0.06% | 216 |
|
|
2019
Q1 | $255K | Sell |
31,277
-4,023
| -11% | -$34.4K | 0.54% | 77 |
|
|
2018
Q4 | $285K | Sell |
35,300
-48,170
| -58% | -$375K | 0.05% | 130 |
|
|
2018
Q3 | $637K | Sell |
83,470
-59,662
| -42% | -$401K | 0.07% | 92 |
|
|
2018
Q2 | $820K | Sell |
143,132
-11,015
| -7% | -$60.6K | 0.73% | 21 |
|
|
2018
Q1 | $735K | Buy |
154,147
+83,066
| +117% | +$427K | 0.64% | 89 |
|
|
2017
Q4 | $349K | Buy |
71,081
+14,208
| +25% | +$68.8K | 0.44% | 89 |
|
|
2017
Q3 | $298K | Buy |
56,873
+5,202
| +10% | +$26.6K | 0.04% | 131 |
|
|
2017
Q2 | $287K | Buy |
51,671
+783
| +2% | +$4.77K | 0.04% | 134 |
|
|
2017
Q1 | $427K | Buy |
50,888
+4,878
| +11% | +$33.9K | 0.08% | 111 |
|
|
2016
Q4 | $291K | Sell |
46,010
-38,897
| -46% | -$202K | 0.09% | 113 |
|
|
2016
Q3 | $374K | Hold |
84,907
| – | – | 0.18% | 84 |
|
|
2016
Q2 | $241K | Buy |
84,907
+58,661
| +224% | +$182K | 0.18% | 102 |
|
|
2016
Q1 | $74K | Buy |
+26,246
| New | +$116K | 0.1% | 147 |
|
Other funds holding BCRX
KCM
ACA
DM
RM
Virtus ETF Advisers's BCRX Position: Q1 2025 in Review
Virtus ETF Advisers sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 46,007 shares — an estimated $346K sold.
Virtus ETF Advisers first reported a position in BCRX in Q1 2016 and held it in 36 quarters. The position peaked at $820K in Q2 2018. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.
- Virtus ETF Advisers reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 46,007 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $346K.
- Virtus ETF Advisers first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's BioCryst Pharmaceuticals position peaked at $820K in Q2 2018.
- 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.